RxDoctor Payments Data

Shahnaz Ali, MD

Internal Medicine · Grand Rapids, MINPI 1922020478

Payments from drug & device makers

$12,845in general payments, 2019–2025

Across 557 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$940
  • Acadia Pharmaceuticals Inc$635
  • Pfizer$605
  • Lilly USA, LLC$604
  • Johnson & Johnson$591
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$1221%
  • Food & beverage$12,31896%
  • Education$4053%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)47$1,091
Astellas Pharma US Inc30$940
Acadia Pharmaceuticals Inc22$635
Pfizer37$605
Lilly USA, LLC19$604
Johnson & Johnson(2 entities)19$591
AstraZeneca(2 entities)26$531
Amgen21$502
Otsuka America Pharmaceutical, Inc.20$497
Novo Nordisk28$494
Sunovion Pharmaceuticals Inc.22$482
Novartis21$393
GSK30$392
Sumitomo Pharma America, Inc.12$324
Boehringer Ingelheim12$288
UCB, Inc.7$281
Bayer10$280
Axsome Therapeutics, Inc.5$277
Teva Pharmaceuticals USA, Inc.12$275
Jazz Pharmaceuticals Inc.3$254
Antares Pharma, Inc.14$236
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$205
Neurocrine Biosciences, Inc.4$188
Neurelis, Inc.6$187
Lundbeck LLC4$180
Amarin Pharma, Inc.17$164
Nestle Healthcare Nutrition Inc.2$147
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)8$141
Daiichi Sankyo Inc.6$119
IBSA Pharma Inc.7$106
Avanir Pharmaceuticals, Inc.4$100
Exact Sciences5$89
E.r. Squibb & Sons, L.L.C.3$87
Eisai Inc.4$75
Takeda Pharmaceuticals U.S.A., Inc.4$75
Biohaven Pharmaceutical Holding Company Ltd.3$70
Alnylam Pharmaceuticals Inc.4$66
CMP Pharma, Inc.3$66
Ultragenyx Pharmaceutical Inc.3$57
Biohaven Pharmaceuticals, Inc.2$56
Otsuka Pharmaceutical Development & Commercialization, Inc.2$48
Halozyme Inc2$43
Therapeuticsmd, Inc.3$41
Sanofi-aventis U.S. LLC2$39
GRT US Holding, Inc.2$36
Almatica Pharma LLC1$28
Gilead2$28
Mayne Pharma Commercial LLC2$26
Regeneron Healthcare Solutions, Inc.2$25
Xeris Pharmaceuticals, Inc.1$24
Inspire Medical Systems, Inc.1$24
Aimmune Therapeutics, Inc.1$22
Globus Medical1$22
Esperion Therapeutics, Inc.1$22
Ardelyx, Inc.1$20
Seqirus USA Inc1$19
Tonix Medicines, Inc.1$19
Merck1$18
Fidia Pharma USA Inc.1$18
Abiomed1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,845 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$43,034
Medicare patients
199
Services billed
626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$165,428
EliquisApixaban145$77,622
OzempicSemaglutide33$45,334
JardianceEmpagliflozin31$35,811
TrulicityDulaglutide29$31,948
TivicayDolutegravir Sodium12$28,595
DescovyEmtricitabine/Tenofov Alafenam11$25,569
MounjaroTirzepatide18$18,398
MyrbetriqMirabegron43$15,878
FarxigaDapagliflozin Propanediol26$10,796
Armour ThyroidThyroid,pork116$10,577
Breo ElliptaFluticasone/Vilanterol11$7,043
Levothyroxine Sodium425$7,012
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,637
ProgesteroneProgesterone, Micronized121$6,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$605$77,622145 claims
Lilly USA, LLCTrulicity, Mounjaro$604$50,34647 claims
Novo NordiskOzempic$494$45,33433 claims
Boehringer IngelheimJardiance$288$35,81131 claims
GileadDescovy$28$25,56911 claims
GSKBreo Ellipta, Trelegy Ellipta, Arexvy$392$18,06336 claims
Astellas Pharma US IncMyrbetriq$940$15,87843 claims
AbbVieArmour Thyroid, Synthroid$1,091$15,410168 claims
AstraZenecaFarxiga$531$10,79626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →